Treatment of SFA lesions with Drug-Eluting technologies

SUSTAINED RELEASE – SUPERIOR RESULTS

Eluvia demonstrated Superior Results in the World’s First Head-to-Head DES SFA Trial. Eluvia is the first and only SFA technology that sustains drug release beyond one year.
Cirse Imperial animation Post Data Release
Prefer to read the study highlights? Sign-up to download the IMPERIAL Data Sheet (DES SFA).


The Growing Evidence Base on Drug Eluting Technologies: A new Focus on Drug Eluting Stent 

  • Results of the IMPERIAL Randomized Controlled Trial of Eluvia vs Zilver PTX
  • Drug Eluting Stent in Peripheral Artery Disease, Critical Limb Ischemia and Below The Knee indications 

Boston Scientific is the only company investing in a complete portfolio of drug-eluting therapies, designed to revolutionize the field, as well as ground-breaking pre-clinical and clinical research that are helping define how to better use the technologies. Our commitment is to bring forward innovative therapies that can make a difference in the lives of patients, and our foundation of more than 15 years of design and development has established our clinical leadership.


Data sheet

IMPERIAL datasheet (DES SFA)

Data sheet

Ranger All-Comers Registry 12 Month-data


DID YOU KNOW

Boston Scientific is the only company investing in a complete portfolio of Drug-Eluting Therapies.

Products Overview

The Eluvia Drug-Eluting Stent delivers unprecedented results in the SFA through its unique SUSTEND™ drug-delivery
technology.
MAJESTIC Trial
The Ranger Drug Coated balloon has been designed to provide consistent and predictable drug delivery through efficient drug transfer and a strong coating integrity.
RANGER SFA RCT
About Drug-Eluting Technologies
Clinical Program
  
Resources Center
   
News & Events
  

WANT TO KNOW MORE?

Join our Drug-Eluting Technologies Community

Sign Up for Product Updates

Receive the latest news of Drug Eluting Technologies

SIGN UP